Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: Results from the 2-year open-label extension of the MUSASHI study

Journal of Rheumatology

Volumn 42, Issue 5, 2015, Pages 799-809

  Ogata, Atsushi ^a   Amano, Koichi ^b   Dobashi, Hiroaki ^c   Inoo, Masayuki ^d   Ishii, Tomonori ^e   Kasama, Tsuyoshi ^f   Kawai, Shinichi ^g   Kawakami, Atsushi ^h   Koike, Tatsuya ⁱ   Miyahara, Hisaaki ^j   Miyamoto, Toshiaki ^k   Munakata, Yasuhiko ^l   Murasawa, Akira ^m   Nishimoto, Norihiro ⁿ   Ogawa, Noriyoshi ^o   Ojima, Tomohiro ^p   Sano, Hajime ^q   Shi, Kenrin ^a   Shono, Eisuke ^r   Suematsu, Eiichi ^j   Takahashi, Hiroki ^s   Tanaka, Yoshiya ^t   Tsukamoto, Hiroshi ^u   Nomura, Akira ^v   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

^d Utazu Hama Clinic   (Japan)

^e TOHOKU UNIVERSITY HOSPITAL   (Japan)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

ⁱ OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^k SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^l Munakata Yasuhiko Clinic   (Japan)

^m Niigata Rheumatic Center   (Japan)

ⁿ Osaka Rheumatology Clinic   (Japan)

^o HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p National Hospital Organization   (Japan)

^q HYOGO COLLEGE OF MEDICINE   (Japan)

^r Shono Rheumatology Clinic   (Japan)

^s SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^t UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^u KYUSHU UNIVERSITY   (Japan)

^v CHUGAI PHARMACEUTICAL CO LTD   (Japan)

more..

Author keywords

Adverse events; Humanized monoclonal antibodies; Rheumatoid arthritis; Subcutaneous injections

Indexed keywords

CORTICOSTEROID; DRUG ANTIBODY; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANAPHYLAXIS; ARTICLE; ASTHMA; CATARACT; CELLULITIS; COLON POLYP; COMPRESSION FRACTURE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; FOOT MALFORMATION; GASTROENTERITIS; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; JOINT DESTRUCTION; JOINT DISLOCATION; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; OSTEOARTHRITIS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SPINE FRACTURE; STOMATITIS; SYNOVITIS; TENDON RUPTURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; AGED; ARTHRITIS, RHEUMATOID; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84940491663     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140665     Document Type: Article

References (24)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
2. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
3. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012;91:30-43.
4. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 2009;3:335-44.
5. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008;6:1-14.
6. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology 2006;45:1575-6.
7. Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2012;5:27-42.
8. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
9. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
10. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
11. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
12. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9.
13. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
14. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
15. Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, et al. Mechanism-based approach using a pharmacokinetic/biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol 2014;54:109-19.
16. Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, et al. A phase 3 study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis (MUSASHI). Arthritis Care Res 2014; 66:344-54.
17. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597-609.
18. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112:3959-64.
19. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68:1580-4.
20. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gomez-Reino J, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4. 6 years of exposure. J Rheumatol 2013;40:768-80.
21. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor ? in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013;65:94-100.
22. Heimans L, van den Broek M, le Cessie S, Siegerink B, Riyazi N, Han KH, et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res 2013;65:1235-42.
23. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011;63:359-64.
24. Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:1653-61.